α-Amylase inhibitory potential of dihydropyrano coumarins: In silico and DFT analysis.

Pooja Garg, Harshil Samir Bhatt, Sanjit Kumar Roy, Sabbasani Rajasekhara Reddy

Abstract read

In one paragraph

Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pooja GargDepartment of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, 632014 India.ORCID https://orcid.org/0000-0001-5286-1652

Harshil Samir BhattCenter for Bio Separation and Technology, Vellore Institute of Technology, Vellore, 632014 India.

Sanjit Kumar RoyCenter for Bio Separation and Technology, Vellore Institute of Technology, Vellore, 632014 India.

Sabbasani Rajasekhara ReddyDepartment of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, 632014 India.ORCID 0000-0002-3813-7235

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coumarin derivatives are one of the naturally occurring bioactive molecule. Dihydropyrano coumarins are one of the medicinally important derivatives of coumarin which have been reported to exhibit various bioactivity. However, there are no reports on their antihyperglycemic activities. Herein, we report their antihyperglycemic potential through α-Amylase inhibition. In this study, a series of 24 derivatives of dihydropyrano coumarins was synthesized and studied for alpha-Amylase inhibitory activity. All the derivatives of dihydropyrano coumarins (4a-x) were screened via molecular docking studies against human pancreatic alpha-Amylase (PDB id: 2QV4) followed by DNS assay to check their α-Amylase inhibitory potential. Six derivatives with Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-024-04194-1.

Indexed as

AntidiabeticsDFT analysisDihydropyrano coumarinsMolecular dockingα-Amylase inhibitor

Identifiers

PMID39807244

DOI10.1007/s13205-024-04194-1

PMCPMC11724822

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.